Orchestra BioMed Holdings (OBIO) stock

Medical device therapies , market cap $366M

Medical device therapies

Worth $366M

After-hours

$5.11

-9.07%

Close $5.62 -6.33%

As of 6:35 PM ET after-hours, delayed 15+ min · Live for Pro members

Quality Score

Below Average

In its industry

#40of 85

Medical Devices

Checks firing

4of 14

Choppy

From 52-week high

-13.5%

under its best in a year

OBIO's Quality Score fell 3 points on Thu, Nov 5, to 5.

See OBIO's 14 chart checksSee it live, free until Saturday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why OBIO beats the market

Up 60% in a year while the S&P 500 rose 15%.

Partnership Revenue Member revenue went from $2.0M to $32.9M; its loss narrowed from $61.0M in fiscal 2024 to $52.7M in fiscal 2025.

Sources: Price history, Nov 4, 2026; 10-K segment note, Mar 12, 2026; Annual reports, Dec 31, 2025

How the business stands and the timeline, for Pro members.

Key facts on OBIO

Key facts on OBIO
Since its Apr 2023 high	Down 73% a $33.6M loss → a $59M loss a year
Latest filing	10-Q, Aug 10 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind OBIO's 5, free with an account →5 more reasons behind OBIO's 5, for Pro members.

OBIO in the news

ReportExpected to report today, after the close. Every 3 months, a company tells everyone how much it sold and earned. It closed flat after its last report. Past reports ›

OBIO catalysts

Coming up

After its last report it closed 0.0%.

Why OBIO scores 5

Below Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means

+4Chart checks 4 of 14 firing right now, one point each
+3Growth sales up 986% on the year, gross margin up 6.8 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.

Long-term trend adds
Run-up adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on OBIO and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 6:35 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when OBIO's Quality Score turns up

See it live, free until Saturday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on OBIO and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

OBIO has 4 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on OBIO, and all 14 on every stock.Get in free →

OBIO RSI today: 47.4, below its 50-day, above its 200-day

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1447.4
Above 30, below 50.
MACD (12, 26, 9)Below signal
Crossed below its signal line today.
50-day average$5.73
The price is 1.9% below it.
200-day average$4.57
The price is 23.0% above it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Aug 27.
ADX 1412.6
Under 25, with +DI below -DI.
Support$5.37
Swing low from Oct 16, 4.4% below the price.
Resistance$5.78
Swing high from Aug 19, 2.8% above the price.
52-week high$6.50
From Oct 1, 15.7% above the price.
52-week low$3.46
From Jan 30, 38.4% below the price.
Chart patternFalling channel
Lines over the Oct 1 and Oct 20 highs and under the Sep 18 and Oct 16 lows.
Bollinger Bands (20, 2)Inside
The bands run from $5.39 to $6.11.
Volume0.7x
Against its 20-day average, for the time of day.

The deep dive on OBIO

What it does and how it makes money5 findingsPartnership Revenue sales rose 1,539% in fiscal 2025, to $32.9M from $2.00M.SEC filing · Mar 12, 2026"Our issued patents expire between March 2026 and April 2041." (10-K for fiscal 2025)SEC filing · Mar 12, 2026
Where it stands3 findingsFor Pro members3 findings on where OBIO stands: its cash, debt, and share count, for Pro members
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades OBIO, for Pro members

8 more findings on OBIO, each with its source, for Pro membersGet in free →

How OBIO ranks in Medical Devices

OBIO is #40 of 85 by Quality Score.

How OBIO ranks in Medical Devices
1	BDXBecton, Dickinson	9/14	19
2	EWEdwards Lifesciences	8/14	19
3	LIVNLivaNova	5/14	18
	MSAMine Safety		Open for its score
	NVCRNovoCure		Open for its score
	OFIXOrthofix Medical		Open for its score
	OSUROraSure		Open for its score
40	OBIOOrchestra BioMed	4/14	5

When does OBIO report earnings, and what happens after?

Expected to report Thu Nov 5, after the close (today). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

0.0%

May 12

Reported	When	Gap	Reaction	5 sessions
May 12, 2026After close	After close	+0.3%	0.0%	-1.5%

OBIO closed higher after 0 of its last 1 report.

Everyone reporting earnings this week

OBIO sales and profit by year

Sales and profit by year

Sales grew in one of the last three years, to $33.5M in 2025. It lost money in each of the four years.

Insiders trading OBIO

OBIO insider trades

4 insiders bought $217K across 7 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyDavid P. Hochman$48KInsiderat $4.79 on Sep 3, filed Sep 8

BuyDavid P. HochmanInsider$48Kat $4.79 on Sep 3, filed Sep 8

All 7 insider filings on OBIO from the last six months, for Pro members.Get in free →

All OBIO insider trades

OBIO's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Andrew Lawrence TaylorChief Financial Officer
Darren ShermanOfficer · 7 trades
David P. HochmanOfficer · 4 trades
Joshua AielloPrincipal Accounting Officer
Jason AryehDirector · 2 trades
Eric S. FainDirector · 1 trade
Chris ClearyDirector
David PacittiDirector

2 more officers and directors file at OBIO. Each page above names the rest.

See insider trades by person

Which ETFs hold OBIO?

In ETFs: OBIO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Orchestra BioMed Holdings

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

86 employeesNew Hope, PAorchestrabiomed.com

What Orchestra BioMed Holdings says it competes with

“The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants.”

From its annual report, SEC filing · Mar 12, 2026

2 more sentences and what it says it does, for Pro membersGet in free →

OBIO's score card

Orchestra BioMed Holdings (OBIO): Quality Score 5, Below Average, #40 of 85 in Medical Devices, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn OBIO's score around: 8 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 8David P. Hochman bought OBIO$48K at $4.79, filed Sep 8

Alerts are optional.

See OBIO's 14 chart checks

See it live, free until Saturday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 5, 2026: OBIO's Quality Score is 5 (Below Average), #40 of 85 in Medical Devices. Insiders bought $217K in the last 6 months (Form 4).

Is OBIO a good stock to buy? What its Quality Score says

OBIO scores 5 today, which Breakaway calls Below Average. It is #40 of 85 in Medical Devices by Quality Score, with 4 of 14 chart checks firing. Up 60% in a year while the S&P 500 rose 15%. Shares: 66.2% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is OBIO's Quality Score?

OBIO scores 5 today, which Breakaway calls Below Average (0 to 5). That is #40 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind OBIO's 5.

Are insiders buying OBIO?

4 insiders bought $217K across 7 filings in the last 6 months. No open-⁠market sales on record. The newest is David P. Hochman, Insider, who bought $48K on Sep 3. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.